The network pharmacological analyses revealed that Cubebin, 2′,6′-dihydroxy-4′-methoxydihydrochalcone, Chalcone base + 3O,1Prenyl, Batatasin IV, and Lucidenolactone were the five core compounds and TP53, SRC, STAT3, PIK3CA, and AKT1 are the five core targets of AOF in the treatment of DKD. Here, AKT1 is linked to diabetic kidney disease.